Is under-utilization of evidence-based drug treatment in patients with heart failure only partially explained by dissimilarity to patients enrolled in landmark trials : a report from the Euro Heart Survey on Heart Failure?
ACE-Is are widely utilized but given in lower doses than proven effective in clinical trials. beta-Blockers are underused and given in lower doses to patients who fulfil the enrolment criteria of relevant landmark trials.
XAGE-1b gene transfection could significantly enhance the immunogenicity of Myc-CaP cells. Therefore, XAGE-1b may be an attractive target for antigen-specific immunotherapy in PCa.